Diacqua

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diacqua

Property Description
Active ingredient Spironolactone
Form Tablet, Oral suspension
Pharmacological class Potassium-sparing Diuretic; Aldosterone Receptor Antagonist
Common use Fluid volume management (edema)
Origin Synthetic, Steroidal Derivative

Diacqua is a synthetic, prescription-only medication containing the single active substance, Spironolactone. Its core identity is based on its dual classification as a potassium-sparing diuretic and a specific aldosterone receptor antagonist. The drug is designed for oral intake, differentiating its administration from methods used for locally acting compounds.

Defining Diacqua: Classification and Active Substance

Diacqua is an antimineralocorticoid that works by targeting the effects of the hormone Aldosterone in the body. The active component, Spironolactone, achieves this by competitively binding to the mineralocorticoid receptors. This foundational mechanism assists in inhibiting the effects of aldosterone, which helps to manage fluid retention. This action ensures the drug promotes the excretion of excess sodium and water from the body.

What Type of Diuretic is Spironolactone?

Spironolactone is characterized as a potassium-sparing diuretic because its unique mode of action facilitates salt and fluid loss while preventing the significant depletion of the essential electrolyte potassium—a property distinguishing it from many high-ceiling diuretics. Diacqua is primarily available as an oral tablet, though the active ingredient is also marketed as an oral suspension, offering flexibility for patient groups who require liquid administration. The single-ingredient composition of Diacqua allows for specific intervention against the aldosterone pathway.

General Purpose and Mechanism Focus

The general purpose of Diacqua is to assist in the systemic management of fluid volume and electrolyte balance. By blocking the hormonal signaling responsible for salt retention, Diacqua generally helps to relieve excess fluid buildup (edema). Furthermore, its classification as a nonselective antagonist means it exhibits a distinct secondary anti-androgenic effect, a factor in its pharmacological profile regarding its interaction with various hormone receptors.

Regulatory References

  1. Spironolactone - LiverTox - NCBI Bookshelf
  2. Spironolactone: MedlinePlus Drug Information

What side effects are possible with Diacqua?

Possible Side Effects and Safety Information

The safety profile of Diacqua (Spironolactone) is based on official government regulatory data, which classifies adverse reactions by the body system affected and by frequency.


Adverse Reaction Scope

Adverse reactions are formally categorized into System-Organ-Classes (SOCs), which include effects on Metabolism and Nutrition Disorders (e.g., electrolyte imbalance), Gastrointestinal Disorders (e.g., nausea), Reproductive System and Breast Disorders (e.g., gynecomastia, menstrual irregularities), and Skin and Subcutaneous Tissue Disorders (e.g., rash).

Key adverse reactions are also classified by frequency:

  • Very Common (ge 1/10): High potassium levels (Hyperkalemia).
  • Common (ge 1/100 to < 1/10): Fatigue, dizziness, nausea, rash.

Serious Adverse Reactions and Restrictions

Regulatory documents identify specific severe and clinically significant reactions. These include potentially fatal hyperkalemia and severe, sometimes life-threatening, skin reactions (such as Stevens-Johnson syndrome or Toxic Epidermal Necrolysis). Acute allergic reactions (hypersensitivity) and agranulocytosis (a severe decrease in white blood cells) are also documented.

Diacqua is strictly contraindicated in specific patient populations due to increased risk. These absolute restrictions include patients with Addison's disease, acute renal insufficiency, other forms of significant renal impairment, or pre-existing hyperkalemia (high blood potassium levels). Safety monitoring for patients often involves regular assessment of serum electrolytes and renal function. The development of gynecomastia is noted to be dose-dependent, meaning the risk may increase with higher doses.

Overdose and Emergency Response

Suspected or confirmed overdosage with Diacqua requires seeking immediate medical attention. The official regulatory profile indicates that acute toxicity is primarily associated with symptoms resulting from fluid and electrolyte imbalance.

Documented Manifestations and Severe Outcomes

An overdose may present with documented signs such as drowsiness, lethargy, mental confusion, dizziness, and gastrointestinal disturbances including nausea, vomiting, and diarrhea. The most severe outcomes are associated with metabolic disturbances, specifically Hyperkalemia (excessive potassium levels), which can lead to life-threatening cardiac arrhythmias. Hyponatremia is also cited. Patients with impaired renal function or severe liver disease are noted to be at a heightened risk for severe outcomes following overdosage.

Emergency Management and Monitoring

There is no specific antidote known for Spironolactone overdosage. Treatment, as described in official regulatory labeling, is entirely symptomatic and supportive, focused on maintaining vital functions and correcting critical fluid and electrolyte imbalances. Immediate actions may include drug discontinuation and, if advised by emergency services, gastric evacuation. Management of severe hyperkalemia may require specific interventions such as intravenous glucose and insulin therapy. Frequent monitoring of serum potassium and creatinine is necessary, and Electrocardiogram (ECG) monitoring may be required due to the potential for serious cardiac events.

Therapeutic Uses of Diacqua

What Diacqua Treats: Main Uses and Benefits

Diacqua (spironolactone) is a therapeutic compound commonly used in supportive symptom management to address symptoms related to systemic imbalance, particularly fluid retention (edema) and high blood pressure.

The application of the medication includes managing conditions characterized by periods of heightened symptoms such as essential hypertension, congestive heart failure with reduced ejection fraction, hepatic cirrhosis with ascites, nephrotic syndrome, and primary hyperaldosteronism.

In these common clinical scenarios, Diacqua assists with maintaining functional stability by helping the body reduce excess fluid and sodium accumulation, which contributes to easing the overall symptom load associated with swelling and high pressure. The patient benefit is focused on symptomatic relief, as the medication supports the patient during difficult episodes by easing distress related to these complex conditions. The use of Diacqua generally supports general well-being during symptomatic phases.


Quick Fact: Supports the management of Fluid Retention (Edema)

Regulatory References

  1. NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Who can and cannot use Diacqua?

Official regulatory documentation for a distinct pharmaceutical product named Diacqua is not available from major governmental health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Consequently, there are no officially published, single-source eligibility or non-eligibility profiles.

However, in some contexts, 'Diaqua' has been used historically as a brand name for Hydrochlorothiazide (HCTZ), a well-documented thiazide diuretic. When considering the established regulatory profile of HCTZ, its use is typically allowed for populations requiring treatment for edema and hypertension. Contraindicated populations, as per official HCTZ labeling, include individuals with anuria (absence of urine production) or a known hypersensitivity to sulfonamide-derived drugs.

Age-related rules generally require cautious use in older adults due to greater sensitivity to fluid and electrolyte changes. Condition-specific restrictions often cite severe renal or hepatic impairment as a reason for not recommending its use.

Eligibility Classification Official Regulatory Status (Based on Hydrochlorothiazide)
Populations for whom use is contraindicated Anuria, known hypersensitivity to sulfonamide-derived drugs
Condition-specific eligibility rules Use not recommended in severe renal or hepatic impairment
Pregnancy and lactation eligibility status Use status determined by prescriber based on risk/benefit analysis

These considerations reflect the established regulatory constraints for the compound associated with the name, but not for a drug named 'Diacqua' itself. The official eligibility structure is defined by the specific contraindications and patient profiles documented in the regulatory label of the active ingredient.

What should I know about interactions with other medicines?

Diacqua (spironolactone) interacts with several medicinal products and substances, primarily due to its role as a potassium-sparing diuretic and its effects on plasma exposure.

Contraindicated and High-Risk Combinations

The co-administration of Diacqua with potassium supplements and the mineralocorticoid receptor antagonist Eplerenone is contraindicated. This restriction is based on the severe risk of additive hyperkalemia (dangerously high potassium levels).

Other medicinal products that significantly increase the risk of severe hyperkalemia when taken with Diacqua include ACE inhibitors, Angiotensin Receptor Blockers (ARBs), other potassium-sparing diuretics, and Heparin products.

Interaction Type Interacting Substance/Class
Additive Hyperkalemia Risk ACE Inhibitors, ARBs, Heparin, Potassium Supplements, Eplerenone
Altered Efficacy NSAIDs, Licorice, Carbenoxolone, Mitotane

Pharmacokinetic and Substance Interactions

Co-administration with food is documented to nearly double the bioavailability (absorption) of spironolactone; consistent administration with respect to meals is therefore required. Diacqua also affects the clearance of other medicines, specifically increasing the plasma exposure of Digoxin and potentially interfering with the laboratory measurement of its concentration. Non-steroidal anti-inflammatory drugs (NSAIDs) may officially reduce the natriuretic (salt-excreting) effect of Diacqua. Additionally, the consumption of alcohol may officially aggravate the risk of orthostatic hypotension.

Mechanism of Action

Mineralocorticoid Receptor Antagonism

Diacqua acts within domains involving receptor-mediated signaling by functioning as a competitive antagonist of the mineralocorticoid receptor (MR) in the distal renal tubules and other tissues. This mechanism suppresses the action of the natural agonist, aldosterone, initiating a cascade that modifies early molecular steps in fluid and electrolyte transport across epithelial barriers.


Electrolyte Transport Modulation

In the distal nephron, Diacqua's MR blockade suppresses the synthesis and upregulation of the epithelial sodium channel (ENaC) and Na^+ / K^+-ATPase activity. The resulting intracellular consequence is a reduction in Na^+ influx and subsequent reabsorption, and a decrease in K^+ secretion. This modulates the balance of fluid and electrolytes, which results in altered pressure-regulating mechanisms.


Non-Mineralocorticoid Receptor Interactions

The drug engages secondary mechanisms, primarily through competitive binding to androgen receptors and, to a lesser extent, progesterone receptors. This allows it to influence the binding equilibrium of androgen receptors, potentially altering downstream effects of endogenous androgens and related signaling patterns.

Dosage and Administration Information

Diacqua (Spironolactone) is for oral administration as both a tablet (available in 25 mg, 50 mg, and 100 mg strengths) and a 5 mg/mL oral suspension. The specific dosage regimen is contingent upon the treated condition. For Essential Hypertension, the typical starting daily dose is 50 mg to 100 mg, which may be taken once daily or in divided doses. The initial dose is typically maintained for at least two weeks before any adjustment is made to assess the full response.

Standard administration involves taking the medicine with a meal, as this condition enhances the systemic absorption of the active substance. When using the liquid formulation, it must be shaken well before use and measured precisely with a calibrated device. Tablets may be crushed and dispersed in liquid for pediatric administration.

Dosing is modified for specific populations. The pediatric population utilizes a weight-based regimen, generally starting from 1 mg/kg daily, not to exceed 100 mg. For older adults, treatment is generally initiated at the lowest possible dose and titrated gradually. For patients in the severe heart failure regimen, the initial dose is 25 mg once daily, with an adjustment to 25 mg every other day (qOD) if necessary for tolerance. The drug is indicated for both short-term use, such as the diagnostic periods for hyperaldosteronism, and long-term maintenance therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diacqua

Evidence for Use in Severe Heart Failure

Diacqua was studied for its use as an add-on therapy for adults with severe heart failure characterized by a reduced ejection fraction (HFrEF). Landmark Randomized Controlled Trials (RCTs) examined long-term outcomes, such as all-cause mortality and hospitalizations. These large-scale studies often monitored patients for an extended period, typically spanning several years.

In the most severely affected HFrEF populations studied, the research described patterns observed in the studies, with findings that included a report of lower rates of all-cause mortality and a report of reduced frequency of heart failure-related hospitalizations compared to placebo. However, when research examined Diacqua in heart failure patients with a preserved or mid-range ejection fraction (HFpEF), the findings were mixed, and outcomes related to survival did not show a consistent pattern.

Evidence for Managing Resistant High Blood Pressure

Research examined the role of Diacqua in conditions involving periods of heightened symptoms, specifically resistant hypertension. Multiple Randomized Controlled Trials (RCTs) were conducted to see how the addition of Diacqua was studied for changes in blood pressure. These trials monitored blood pressure using both clinic measurements and 24-hour ambulatory monitoring.

Studies reported how symptoms evolved in the observed populations, with data showing patterns related to reductions in both the systolic and diastolic blood pressure readings. Comparative studies explored its use against other add-on agents, and findings indicated a change in blood pressure measurements in this population.

Evidence for Fluid Management in Cirrhosis

Diacqua was evaluated in patients with fluid accumulation (ascites and edema) stemming from hepatic cirrhosis. Researchers conducted Randomized Controlled Trials (RCTs) comparing Diacqua used alone versus in combination with other diuretics. The trials monitored outcomes related to systemic or functional imbalance, such as the rate of fluid mobilization and changes in serum electrolytes.

Some comparative trials reported a more rapid achievement of diuresis in some studies, but other studies indicated that the difference between combination and sequential therapy was not fully established across all patient groups.

Where the Research Remains Uncertain

Despite the breadth of the evidence, certainty remains low in certain areas. For instance, long-term effects are not fully established regarding the reduction of major cardiovascular events in resistant hypertension trials. Furthermore, the evidence quality varies across studies for edema and fluid retention indications. Research is ongoing to address these gaps and provide clearer insight into long-term outcomes and effects across diverse patient groups.

Key Studies & References

  1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure (RALES)

Frequently Asked Questions (FAQ)

Common questions about Diacqua (FAQ)


Q: How quickly should I expect to feel the effects of Diacqua after starting it?

Official prescribing information indicates that the full therapeutic response is not immediately observed. For some conditions, such as essential hypertension, the initial dose must be maintained for at least two weeks to assess the full response.


Q: What are the most common side effects people experience with Diacqua?

According to official regulatory data, the most commonly reported side effect is Hyperkalemia (high potassium levels). Other side effects that are common (≥ 1/100 to < 1/10) include fatigue, dizziness, nausea, and skin rash.


Q: Are there any long-term side effects associated with taking Diacqua?

Regulatory documents note that the development of gynecomastia (breast enlargement in males) is a dose-dependent side effect that may occur during long-term use. Concerns regarding tumorigenic effects have also been raised in non-human long-term animal studies, which are noted in the regulatory documents.


Q: What happens if I miss a dose of Diacqua?

Regulatory patient information often provides general instructions for a missed dose, such as taking it when remembered unless it is nearly time for the next dose. Any specific missed dose action should always be confirmed with a healthcare provider.


Q: How does Diacqua compare to other medications for the same condition (without comparing efficacy)?

Diacqua is classified as an aldosterone receptor antagonist, which means it blocks the action of the aldosterone hormone. This results in its designation as a potassium-sparing diuretic, a specific mechanism of action that is distinct from other diuretic classes and heart medicines.


Q: Can older adults safely take Diacqua?

Regulatory guidance notes that because older adults may be more sensitive to fluid and electrolyte changes, treatment is generally initiated at the lowest dose and increased gradually. This approach is intended to manage potential risks in this population.


Q: What should I avoid eating or drinking while taking Diacqua?

It is advised to avoid alcohol consumption, as official information states it may increase the risk of orthostatic hypotension (dizziness or fainting when standing up). The label also notes that taking the medication with a meal is required to enhance the absorption of the active substance.


Q: Do I need to get regular blood tests while on Diacqua?

Yes, safety monitoring for patients on this medication typically involves the regular assessment of serum electrolytes (like potassium) and renal function. This is necessary due to the drug's mechanism and the noted risk of hyperkalemia and kidney impairment.


Q: What makes Diacqua different from Acetazolamide (if similar mechanism)?

The key difference is the drug’s target. Diacqua is a competitive antagonist of the mineralocorticoid receptor (Aldosterone Receptor Antagonist), whereas Acetazolamide is classified as a carbonic anhydrase inhibitor. They influence fluid balance through separate biochemical pathways.


Q: Can Diacqua be crushed or split if difficulty swallowing?

Official administration advice confirms that tablets may be crushed and dispersed in liquid specifically for use in the pediatric population. The active ingredient is also available as an oral suspension formulation for patients who require liquid administration.


Q: Does Diacqua interact with hormone replacement therapy (HRT)?

The drug is known to engage in competitive binding with androgen receptors and, to a lesser extent, progesterone receptors. This pharmacological action suggests a potential for interaction or influence on hormonal therapies.


Q: Is Diacqua known to interact with alcohol?

Yes, official drug information states that consuming alcohol may officially aggravate the risk of orthostatic hypotension. This is a sudden drop in blood pressure when changing positions, which can cause dizziness or fainting.


Q: Can Diacqua interact negatively with common supplements like vitamins or herbal remedies?

Co-administration with potassium supplements is strictly prohibited due to the severe risk of dangerously high potassium levels. Regulatory information states that all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products should be discussed with a healthcare provider.


Q: Is it true that Diacqua can affect sleep patterns?

The official adverse reaction reports include effects on the nervous system such as drowsiness and dizziness. While not a direct statement about sleep patterns, these side effects are listed and may indirectly affect a patient’s sleep quality.


Q: Is it safe to take Diacqua if I have kidney problems?

Diacqua is strictly contraindicated (prohibited) in patients with acute renal insufficiency or other forms of significant renal impairment. A healthcare provider should be consulted regarding suitability when any kidney problems exist.


Q: Can Diacqua cause dehydration, and what are the signs?

The product’s function is to increase fluid excretion, and adverse effects related to electrolyte imbalance and increased thirst have been officially reported. These effects are managed through appropriate clinical monitoring.


Q: How long does Diacqua typically stay in your system?

The active metabolites that contribute to the drug's effects have half-lives of approximately 14 to 17 hours after steady state is reached. Generally, it takes approximately four to five half-lives for most of a substance to be eliminated from the body.


Q: Can taking Diacqua lead to gout attacks?

Regulatory documents list Hyperuricemia (high levels of uric acid) as a possible disease interaction with this medication. Since hyperuricemia is the underlying cause of gout, patients with a history of the condition may require caution.


Q: Can Diacqua affect my ability to drive or operate machinery?

Due to reported somnolence (drowsiness) and dizziness, official warnings advise that patients should take care when operating machinery or driving until their response to the medication is known.


Q: Is there a generic version of Diacqua available?

Yes, the active ingredient in Diacqua, which is Spironolactone, has FDA-approved generic versions available in multiple strengths from various manufacturers.


Q: Does Diacqua cause stomach upset or digestive issues?

Official regulatory data reports include nausea and vomiting as common adverse reactions. Other issues, including stomach cramping, burning, and tenderness, are also documented as potential gastrointestinal disorders.


Q: Can I take Diacqua if I am taking a blood thinner?

Official drug interaction warnings state that the co-administration of Diacqua with Heparin products (a type of blood thinner) significantly increases the risk of severe hyperkalemia (dangerously high potassium). This combination is listed as high-risk.


Q: Do I need to adjust my salt intake while on Diacqua?

The drug's primary function is to promote the excretion of excess salt (sodium) and water. While specific official instructions for general dietary sodium intake adjustment are not typically provided, any excessive potassium intake should be avoided.


Q: Can Diacqua worsen or trigger acid reflux?

Adverse effects reported in the gastrointestinal system include heartburn and gastric inflammation. These symptoms may be related to or worsen existing symptoms of acid reflux.


Q: Is there any research on Diacqua's use in pediatric populations?

Official prescribing information provides specific weight-based dosing guidance for the pediatric population. However, the label does not typically include a summary of dedicated research findings or clinical trial evidence for pediatric use.


Q: Does Diacqua interact with vitamins D or B12 supplements?

The regulatory label advises patients to tell their doctor about all vitamins and nutritional supplements they are taking. Patients are advised in regulatory documents to discuss all supplements, vitamins, and nonprescription products with a healthcare provider.


Q: Can Diacqua cause skin sensitivity to the sun?

Official adverse reaction data reports several severe skin reactions, including rash and conditions like Stevens-Johnson syndrome. While specific photosensitivity may not be explicitly listed, these skin issues indicate a potential for dermal adverse effects.


Q: Are there any specific warnings for people with diabetes taking Diacqua?

Yes, official regulatory documents list diabetes as one of the disease interactions with this medication. This indicates that patients with diabetes may require careful monitoring and caution when using this drug.


Q: Is Diacqua safe during pregnancy or while breastfeeding?

Official warnings state that, based on animal findings, the drug may affect sex differentiation of the male fetus. For breastfeeding, the use requires a professional decision to either stop breastfeeding or discontinue the drug, based on the importance of the medication to the mother.


Q: Why does the packaging list so many potential drug interactions?

The extensive list of potential interactions is due to the drug’s core mechanism. It acts as a non-selective antagonist that affects key body systems, including electrolyte balance (raising potassium) and the clearance of other medicines (e.g., Digoxin), resulting in numerous drug combinations requiring caution.


Q: How long does it take for Diacqua to be fully eliminated from the body?

The active components of the drug have half-lives of approximately 14 to 17 hours. Generally, it takes approximately four to five half-lives for most of a substance to be eliminated from the body.

How should Diacqua be stored and disposed of?

Storage Conditions and Container Rules

Diacqua (spironolactone) tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). Storage excursions are permitted up to 30 C. It is mandatory to protect the medication from light and store it away from excess moisture. The product should be kept in a tight, light-resistant container and maintained with a tightly closed lid.


Handling and Disposal

To ensure safety, Diacqua must be stored out of the reach of children, typically requiring a child-resistant closure. Any unused or expired medicine and waste material must be disposed of in accordance with local requirements. It is essential to avoid discharge of pharmaceutical waste into drains, water courses, or the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diacqua found in:

A-Z Index: